CYP19A1 and breast cancer: The fact that GP88 has been shown to be a potent proliferation and anti-apoptotic factor for breast cancer cells [26,33,34] would suggest that GP88 confers resistance to the killing effect of letrozole by providing growth and survival advantage to the cells rather than by blocking estrogen response or by inhibiting aromatase activity.